GRAd-COV2

GRAd-COV2
Vaccine description
TargetSARS-CoV-2
Vaccine typeViral vector
Clinical data
Routes of
administration
Intramuscular

GRAd-COV2 is a COVID-19 vaccine candidate developed by ReiThera Srl and Lazzaro Spallanzani National Institute for Infectious Diseases.[1][2] It is based on a novel replication defective Gorilla Adenovirus and encodes for SARS-COV-2 full length prefusion stabilized Spike protein.[1] More specifically, the vector used is the simian group C adenovirus GRAd32, isolated from a captive gorilla, with a genome deleted of the entire E1 and E3 regions and the native E4 region replaced with the E4 orf6 of human adenovirus 5 (hAd5).[3]

References

  1. 1 2 "GRAd-COV2 Vaccine Against COVID-19". ClinicalTrials.gov. United States National Library of Medicine. 7 January 2021. NCT04528641.
  2. "ReiThera Announces its GRAd-COV2 COVID-19 Vaccine Candidate is Well Tolerated and Induces Clear Immune Responses in Healthy Subjects Aged 18–55 Years". ReiThera Srl. Yahoo! Finance. 24 November 2020. Retrieved 12 January 2021.
  3. Capone S, Raggioli A, Gentile M, Battella S, Lahm A, Sommella A, et al. (April 2021). "Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19". Molecular Therapy. 29 (8): 2412–2423. doi:10.1016/j.ymthe.2021.04.022. PMC 8062434. PMID 33895322.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.